Mandate

Vinge has advised Aprea Therapeutics in connection with its listing on Nasdaq, New York

Vinge has advised Aprea Therapeutics, Inc. and its subsidiary Aprea Therapeutics AB in connection with its listing on Nasdaq, New York.

The initial public offering price was set to $15 and the biopharmaceutical company sold 6.5 million shares in the IPO to raise $97.75 million. Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing cancer therapeutics.

 
Vinge’s team has primarily consisted of Kristina Ekberg, Charlotte Levin, Maria Schultzberg, Anna Thoms and Stina Bengtsson.

Related

Vinge advises Axcel in connection with the sale of Loopia Group to team.blue

Vinge advises Axcel V in connection with the sale of Loopia Group to team.blue, Europe’s leading digital enabler for entrepreneurs and SMBs and backed by Hg, a leading investor in European and transatlantic software and services businesses.
May 23, 2024

Vinge advises Humana in its acquisition of Team Olivia Norge AS

Humana Group ("Humana") strengthens its offering of high-quality care services in Norway as Human Care Holding AS ("Humana Norway") has entered into an agreement to acquire Team Olivia Norge AS for a purchase price of million SEK 341 on a cash- and debt-free basis.
May 17, 2024

Vinge advises Stendörren in connection with issuance of green capital securities and tender offer

Vinge has advised Stendörren Fastigheter AB in connection with its issuance of green subordinated and perpetual capital securities in an amount of SEK 300 million (within a framework of SEK 400 million) and its parallel tender offer in respect of its previously issued capital securities.
May 17, 2024